0001493152-26-038039 Sample Contracts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 14th, 2026 • Dyadic International Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 13, 2026, between Dyadic International, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 14th, 2026 • Dyadic International Inc • Biological products, (no disgnostic substances)
This Agreement is made pursuant to the Securities Purchase Agreement with respect to the sale of Warrants under Regulation D, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).
STOCK PURCHASE AGREEMENTStock Purchase Agreement • August 14th, 2026 • Dyadic International Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 13, 2026, between Dyadic International, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”).
PERSONAL AND CONFIDENTIALPlacement Agent Agreement • August 14th, 2026 • Dyadic International Inc • Biological products, (no disgnostic substances) • New York
The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis” or the “Placement Agent”) will act as the placement agent on a “best efforts” basis in connection with the proposed Registered Direct and PIPE Offering (the “Placement”) by Dyadic International, Inc. (collectively, with its subsidiaries and affiliates, the “Company”) of units consisting of its shares of Common Stock and warrants to purchase its shares of Common Stock (the “Securities”). This placement agent agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company expressly acknowledges and agrees that Aegis’s obligations hereunder are on a reasonable “best efforts” basis only and that the execution of this Agreement does not constitute a commitment by Aegis to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Aegis with respect to securing an
PIPE COMMON WARRANT TO PURCHASE COMMON STOCK DYADIC INTERNATIONAL, INC.Pipe Common Warrant • August 14th, 2026 • Dyadic International Inc • Biological products, (no disgnostic substances) • New York
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and on or prior to 5:00 p.m. (New York City time) on the fifth anniversary of the Release Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Dyadic International, Inc., a Delaware corporation (the “Company”), up to [●] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. Subject to the provisions of Section 2.3, the purchase price of one (1) share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2.2.